Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA)

Table 1 MCDA EVIDEM framework version 4.0 adapted to evaluation of medicines indicated for rare diseases

QUANTITATIVE CRITERIA: MCDA Core Model
DOMAIN: Disease needs
Disease severity
Unmet needs
DOMAIN: Comparative outcomes of interventions (selexipag vs iloprost)
Comparative efficacy/effectiveness
Comparative safety/tolerability
Comparative patient-perceived health/patient reported outcomes (PRO)
DOMAIN: Type of benefit provided by selexipag
Type of preventive benefit
Type of therapeutic benefit
DOMAIN: Comparative economic consequences of interventions (selexipag vs iloprost)
Comparative cost of intervention
Comparative other medical costs
Comparative other non-medical costs
DOMAIN: Knowledge about selexipag
Quality of evidence
Expert consensus/clinical practice guidelines (CPG)
CONTEXTUAL CRITERIA: MCDA Contextual Tool
Population priorities and access
Common goals and specific interests
System capacity and appropriate use of intervention
Opportunity costs and affordability

ISSN: 1750-1172